TITLE:
The Tumor Infiltrating Lymphocytes (TILs): Did We Find the Missed Piece of the Huge Puzzle?
AUTHORS:
Suzan Samir Elsharkawy, Mohamed Abd Elrheem, Samia Abd Elrheem
KEYWORDS:
Tumor Infiltrating Lymphocytes, Cancer, Checkpoint Inhibitor, Adoptive Cell Therapy, T Cell Receptor (TCR), Moist Heat, Pan-Cancer Therapy, Squamous Cell Carcinoma, Basal Cell Carcinomas
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.11 No.2,
February
25,
2021
ABSTRACT: Tumor infiltrating lymphocytes (TILs) are used in evaluating
the prognosis and determining treatment of different types of cancer with variable
degrees of success. The usage of checkpoint inhibitor immunotherapy as a treatment
variety for cancer and Adoptive cell therapy is associated with many complications,
severe side effects and high expenses. Recently, in a limited number of metastatic
GIT and breast cancers, the identification of T-cell specific against so-called
tumor neo-antigens and Adoptive transfer of those lymphocytes resulted in some improvement.
In 2020, Detection of a T cell receptor (TCR) in a T cell clone that recognized
and killed most human cancer cell lines in vitro via the monomorphic MHC class I-related
protein MR1, offers an opportunity for pan-cancer therapy Twenty three years earlier,
Moist Heat was used successfully to activate a whole different and new immune response
that was able to detect genetic mutation in the affected cancer cells and cured
many cases of squamous and basal cell carcinomas. In this commentary review, we
aimed to revise the literature for updates of TILs usage in cancer prognosis and
treatment.